Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fanapt
Pharma
Cycle's 2nd hostile takeover bid in 5 months rejected by Vanda
For the second time in five months, Vanda Pharmaceuticals has rejected an $8-per-share takeover bid from Cycle Pharmaceuticals of England.
Kevin Dunleavy
Oct 14, 2024 3:18pm
Vanda rejects buyout offers from Future Pak, Cycle
Jun 20, 2024 9:27am
Vanda gets $466M takeout bid from Cycle Pharma
Jun 6, 2024 10:10am
Vanda turns back on hostile takeover bid by CDMO Future Pak
Apr 18, 2024 11:01am
15 years later, Vanda secures another FDA nod for Fanapt
Apr 3, 2024 11:04am
OPDP ramp-up spawns new letter warning Vanda for omitted risks
Nov 1, 2018 10:59am
